Intellectual Property:  Dr. Le Poole and Dr. Nguyen are the inventors on the provisional patent on the therapeutic formulation. The company holds an option to license the IP as the patent gets awarded. In addition, Temprian Oncology works actively with the development of additional IP and trade secrets characteristic for oncology-oriented innovations.

The Market: The Total Available Market (TAM) for the Supercarriers addressing stage III and IV melanoma is estimated to be $1.5B in the United Sates. Considering the complex nature of cancer therapies, we estimate 2/3 of the market to be within our reach, putting the Serviceable Available Market (SAM) at $1B.  While the efficacy of the drug in combination with the existing standards-of-care will ultimately determine the demand, we estimate the Serviceable Obtainable Market (SOM) to range between $100M and $300M.  The international market is measured in billions of dollars.

Investors / Inquiries: Please contact Kettil Cedercreutz, PhD, CEO at CEO@TemprianOnc.com (513)374-1180.
‍
Temprian Oncology's laboratories are hosted at the Querrey InQubation Laboratory hosted on Northwestern University's Evanston Campus.

Laboratory:  
Temprian Oncology Inc.
Querrey InQubation Laboratory
1801 Maple Avenue
Evanston, IL 60201

Administration:
Temprian Oncology Inc.
411 N Oak Park Avenue
Unit I
Oak Park, IL 60302
‍

‍